賽生藥業(06600.HK)年度實現純利7.5億元 同比增長22.6%
格隆匯 3 月 26日丨賽生藥業(06600.HK)發佈公吿,截至2020年12月31日止年度,集團錄得收入約為人民幣19.186億元,較去年增長約12.3%;毛利約為人民幣14.905億元,較去年增長約13.4%;純利約為人民幣7.537億元,較去年增長約22.6%;每股基本盈利約為人民幣1.38元,較去年增長約22.1%;及每股攤薄盈利約為人民幣1.35元,較去年增長約19.5%。
已上市產品的增長:銷售自有產品日達仙的收入由2019年同期增長16.2%至2020年的人民幣15.682億元。公司自2020年12月開始以進口商及分銷商身份於中國若干省份分銷擇泰,並因此開始產生銷售擇泰的收入。
在研產品的擴張:2020年,公司將三款候選產品添加至公司的在研候選藥物組合。2020年3月,公司自Tarveda Therapeutics獲得PEN-866(一種治療實體瘤的選擇性精確腫瘤候選藥物)的引入授權。2020年6月,公司自EpicentRx, Inc獲得RRx001(一種治療實體瘤的耐受性較佳的下一代小分子免疫療法)的引入授權。2020年12月,公司自Y-mAbs Therapeutics, Inc.獲得兩種候選藥物(用於治療高危神經母細胞瘤的Naxitamab及用於治療CNS ╱神經母細胞瘤的軟腦膜轉移的Omburtamab)的引入授權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.